1857296-39-9

Basic information

• Product Name: methyl 5-bromo-4-methyl-1H-indole-2-carboxylate
• CAS NO: 1857296-39-9
• Molecular Weight: 268.11
• Mol File: 1857296-39-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 5-bromo-4-methyl-1H-indole-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-bromo-4-methyl-1H-indole-2-carboxylate(1857296-39-9)
• EPA Substance Registry System: methyl 5-bromo-4-methyl-1H-indole-2-carboxylate(1857296-39-9)

Safety Data

• Hazardous Substances Data: 1857296-39-9(Hazardous Substances Data)

Upstream product

• 83647-40-9 3-bromo-2-methylbenzaldehyde 
• 83647-43-2 3-bromo-2-methylbenzyl alcohol 
• 76006-33-2 3-bromo-2-methylbenzoic acid 

Downstream Products

• 50536-58-8 5-bromo-4-methyl-1H-indole-2-carboxylic acid 

Relevant articles and documents

METHODS OF PROMOTING BETA CELL PROLIFERATION

The present disclosure provides methods of promoting proliferation of a pancreatic cell. The methods are useful for the treatment of diabetes and other diseases characterized by impaired glucose tolerance.

Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL)

Development of potent small molecule inhibitors of protein-protein interactions with optimized druglike properties represents a challenging task in lead optimization process. Here, we report synthesis and structure-based optimization of new thienopyrimidine class of compounds, which block the protein-protein interaction between menin and MLL fusion proteins that plays an important role in acute leukemias with MLL translocations. We performed simultaneous optimization of both activity and druglike properties through systematic exploration of substituents introduced to the indole ring of lead compound 1 (MI-136) to identify compounds suitable for in vivo studies in mice. This work resulted in the identification of compound 27 (MI-538), which showed significantly increased activity, selectivity, polarity, and pharmacokinetic profile over 1 and demonstrated a pronounced effect in a mouse model of MLL leukemia. This study, which reports detailed structure-activity and structure-property relationships for the menin-MLL inhibitors, demonstrates challenges in optimizing inhibitors of protein-protein interactions for potential therapeutic applications.